期刊文献+

肿瘤发生的潜在分子基础(2)(英文) 被引量:1

Underlying Molecular Mechanisms of Tumorigenesis (2)——Unbalance between Proliferation and Cell Death
原文传递
导出
摘要 肿瘤发生是一个多步骤过程。绝大多数人肿瘤由产生了系列相继变化的单一细胞形成。这些变化导致细胞有丝分裂信号或生长控制的细微异常 ,逐步赋予细胞赘生的特性 ,直至细胞形成恶性肿瘤。防御肿瘤发生的一个重要机能是诱导细胞死亡 ,这种机能持续不断地清除机体内多余的 ,受损的或变异的细胞。对肿瘤细胞增殖优势的分子机理的认识 ,揭示了许多肿瘤细胞如何应答异常有丝分裂信号的内在现象 ,而蛋白磷酸激酶是介导这些信号通路的主体。天然细胞或病毒蛋白能作为细胞死亡效应子发挥作用 ,尤其有意义的是 ,有些细胞和病毒蛋白具有肿瘤特异性细胞死亡效应 ,可望发展成为新的抗肿瘤治疗制剂。 Cancer formation is a multi-step process. Most, if not all, human tumors develop through sequential genetic alterations in a single cell. These alterations cause subtle aberrations in mitogenic signaling or growth control, confer increasingly neoplastic characteristics on cells, and culminate in cells that are able to form malignant tumors. An important mechanism to prevent tumorigenesis is the induction of cell death that takes place continuously in many tissues of our body to remove unwanted, damaged or aberrant cells. Understanding the molecular mechanisms underlying the proliferative advantage of cancer cells has revealed many insights into how tumor cells respond to the altered mitogenic signaling, which predominantly involve protein kinases. Natural cellular or viral proteins may function as death effectors. Of particular interest, some of these cause tumor-specific cell death, which makes possible the development of novel anti-cancer therapeutic agents. Here, unbalance between proliferation and cell death underlying tumorigenesis (part 1) will be discussed. The effectors of survival and death underlying tumorigenesis will be discribed in part 2.
出处 《医学分子生物学杂志》 CAS CSCD 2004年第4期195-206,共12页 Journal of Medical Molecular Biology
关键词 肿瘤发生 分子基础 细胞衰老 细胞转化 细胞凋亡 细胞死亡抑制因子 磷酸激酶 细胞死亡效应蛋白 tumorigenesis senescence immortalization apoptosis death inhibitors kinases death effectors
  • 相关文献

参考文献76

  • 1Stommel JM, Marchenko ND, Jimenez GS, et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J, 1999, 18:1 660-72.
  • 2Roth J, Dobbelstein M, Freedman DA, et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J, 1998, 17:554-64.
  • 3Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3:673-82.Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat R
  • 4Sprick MR, Rieser E, Stahl H, et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signaling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J, 2002, 21: 4 520-30.
  • 5Shtrichman R, Sharf R, Barr H, et al. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc Natl Acad Sci USA, 1999, 96: 10 080-5.
  • 6Schoemaker MH, Ros JE, Homan M, et al. Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. J Hepatol, 2002, 36:742-50.
  • 7Jordan BW, Dinev D, LeMellay V, et al. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J Biol Chem, 2001, 276: 39 985-9.
  • 8Sun XM, Bratton SB, Butterworth M, et al. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem, 2002, 277: 11 345-51.
  • 9Wang HW, Sharp TV, Koumi A, et al. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J, 2002, 21:2 602-15.
  • 10Kamradt MC, Chen F, Sam S, et al. The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem, 2002, 277: 38 731-6.

二级参考文献25

  • 1Pietersen AM,van der Eb MM,Rademaker HJ,et al.Specific tumor-cell killing with adenovirus vectors containing the Apoptin gene.Gene Ther,1999,6:882-92.
  • 2van der Eb MM,Pietersen AM,Speetjens F,et al.Gene therapy with Apoptin induces regression of xenografted human hepatomas.Gene Ther,2002,9:53-61.
  • 3Guelen L,Paterson H,Gaken J,et al.TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells.Oncogene,2004,23:1 153-65.
  • 4Leliveld SR,Zhang YH,Rohn JL,et al.Apoptin induces tumor-specific apoptosis as a globular multimer.J Biol Chem,2003,278:9 042-51.
  • 5Leliveld SR,Dame RT,Mommaas MA,et al.Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA.Nucleic Acid Res,2003,31:4 805-13.
  • 6Danen-van Oorschot AAM,Zhang YH,Leliveld SR,et al.Importance of nuclear localization of Apoptin for tumor-specific induction of apoptosis.J Biol Chem,2003,278:27 729-36.
  • 7Danen-van Oorschot AAM.Apoptin,a viral protein that induces tumor-specific apoptosis.Thesis,Leiden University,Leiden,The Netherlands,2001.
  • 8Noteborn MHM,de Boer GF,van Roozelaar DJ,et al.Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle.J Virol,1991,65:3 131-9.
  • 9Bao J,Zervos AS.Isolation and characterization of Nmi,a novel partner of Myc proteins.Oncogenes,1996,16:2 171-6.
  • 10Chen CM,Huang SP,Chang YF,et al.The viral death protein Apoptin interacts with Hippi,the protein interactor of Huntingtin-interacting protein 1.Biochem Biophys Res Commun,2003,305:359-64.

共引文献6

同被引文献21

  • 1章应慧,Rohn J,Abrahams JP,Noteborn MHM.肿瘤发生的潜在分子基础(1)(英文)[J].医学分子生物学杂志,2004,1(3):129-139. 被引量:2
  • 2吴涛,张西臣,李建华,张国才,杨举,宫鹏涛.不同旋毛虫粗抗原对BALB/c小鼠体内SP2/0肿瘤抑制作用观察[J].中国病原生物学杂志,2007,2(4):269-272. 被引量:12
  • 3Penyman SV’ Sylvester KG. Repair and regeneration:opportunitiesfor carcinogenesis from tissue stem cells[J].J Cell MolMed006,10(2):292-308.
  • 4Bodrogi I.Effect of angiogenesis inhibitors on renal cellcarcinoma[J].Magy 0nkol007,51(2): 145-153.
  • 5Reang P, Gupta M,Kohli K.Biological response modifiers incancer[J].Med Gen Mec2006,8(4):33.
  • 6Nishida N,Yano UNishida T,et al.Angiogenesis in cancer[J].VascHealth Risk Manag006,2(3): 213-219.
  • 7DuBois S, Demetri G. Markers of angiogenesis and clinicalfeatures in patients with sarcoma[J]. Cancer007,109(5):813-819.
  • 8Timar J,Kopper L3odrogi I.Molecular pathology and taigetedtherapy of clear cell renal cancer[J].Magy 0nkol?2006,50(4):309-314.
  • 9Pedraza-Farina LG.Mechanisms of oncogenic cooperation incancer initiation and metastasis[J].Yale J Biol Med2006,79(3-4):95-103.
  • 10Ogivie BM,Simpson EKeller R.Tumour growth in nematode-infected animals[J] .Lancet,1971,1(7701):678-680.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部